Posts for Ticker ‘CRXL’

Top 10 Analyst Upgrades and Downgrades (AEZS, AXP, ARTC, BRCD, GLW, CRXL, GS, IGT, MOT, TRA)

These are ten of the top analyst research upgrades, downgrades, and initiations seen early this Tuesday morning with about two hours until the market opens:

Aeterna Zentaris (AEZS) Cut to Sector Perform at RBC; cut at Canaccord and at Desjardins also.
American Express (AXP) Raised to Outperform at KBW.
Arthrocare (ARTC) Raised to Buy at Canaccord.
Brocade (BRCD) Raised to Strong Buy at S&P.
Corning (GLW) Raised to Outperform at Oppenheimer.
Crucell (CRXL) Cut to Sell at ING.
Goldman Sachs (GS) Raised to Buy at Pali.
International Game Tech (IGT) Raised to Overweight at JPMorgan.
Motorola (MOT) Started as Buy at Canaccord.
Terra Industries (TRA) Started as Overweight at JPMorgan.

JON C. OGG
AUGUST 18, 2009

Posted on: August 18, 2009 – 7:53 am in Analyst Calls, , , , , , , , , ,

Swine Flu Lessons from SARS, Mad Cow & Bird Flu of Past (GILD, BCRX, NVAX, GNBT, VICL, AVII, CRXL, RHHBY, GSK, SFD, EWW, MXF)

burning-money-pic27Monday is looking like a SWINE FLU speculative flu stock stock bonanza, and we want to caution about some of the lessons of scares in the past of SARS, bird flu, Mad Cow, and even hoof & mouth as similar references.  The two approved drug treatments, not vaccines, which are being released are Tamiflu made by Roche (OTC: RHHBY) and Relenza made by GlaxoSmithkline (NYSE: GSK).  Gilead Sciences, Inc. (GILD) gets royalties from Roche for Tamiflu, and its shares are indicated north of $48.00 after a $45.80 close on Friday.  There are also waves of tier-two and tier-three stocks which could move on this news, but be advised that we have seen these pops in the past from SARS and Bird Flu which were followed ultimately by lower share prices and many of the speculative players disappeared.

Of the tier-two stocks, you have BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) and Novavax, Inc. (NASDAQ: NVAX).  Of the tier-three stocks you have Generex Biotechnology Corp. (NASDAQ: GNBT), Vical Inc. (NASDAQ: VICL), AVI Biopharma, Inc. (NASDAQ: AVII), and Crucell NV (NASDAQ: CRXL).  More descriptive data has been provided for each move.   On another scale, Smithfield Foods Inc. (NYSE: SFD), the iShares MSCI Mexico Investable Market Index (NYSE: EWW), and The Mexico Fund, Inc. (NYSE: MXF) have exposure here as well.
Read More »

Posted on: April 27, 2009 – 6:40 am in Biotech, Drug companies, Food, Medical, Pharmaceuticals, Regulation, Research, Trading Alert, , , , , , , , ,

Top Pre-Market Analyst Upgrades (AXYS, CRXL, DFT, LVLT, LGND, NOC, OXGN, PFE)

money_stack_pic9These are some of this morning’s top pre-market analyst upgrades and positive research calls from Wall Street this Thursday morning with over two hours until the market opens:

  • Axsys Technologies (AXYS) Raised to Overweight at JPMorgan.
  • Crucell (CRXL) Started as Buy at Jefferies.
  • DuPont Fabros Technology (DFT) Raised to Outperform at Wachovia.
  • Level 3 Communications (LVLT) Raised to Hold at Stanford.
  • Ligand Pharmaceuticals (LGND) Started as Buy at Merriman Curhan Ford.
  • Northrop Grumman (NOC) Raised to Outperform at Bernstein.
  • Oxigene (OXGN) Started as Buy at Merriman Curhan Ford.
  • Pfizer (PFE) Raised to Outperform at Leerink Swann.

Jon C. Ogg
February 12, 2009

Posted on: February 12, 2009 – 7:29 am in Analyst Calls, , , , , , , , , ,

Top Pre-Market Analyst Upgrades (MDRX, BDX, ED, CRXL, CSX, RTN, SGR, SNN)

Money_stack_picThese are the early bird upgrades and positive analyst calls we have seen from Wall Street this Friday morning:

  • Allscripts-Misys (NASDAQ: MDRX) Raised to Outperform at William Blair.
  • Becton Dickinson (NYSE: BDX) Raised to Overweight at Morgan Stanley.
  • Consolidated Edison (NYSE: ED) Raised to Buy at Citigroup.
  • Crucell (NASDAQ: CRXL) Raised to Buy at RBS.
  • CSX (NYSE: CSX) Raised to Buy at Deutsche Bank.
  • Raytheon (NYSE: RTN) Raised to Buy at Goldman Sachs.
  • Shaw Group (NYSE: SGR) Cut to Hold at Citigroup.
  • Smith & Nephew (NYSE: SNN) Raised to Neutral at JPMorgan.

Jon C. Ogg
January 9, 2009

Posted on: January 9, 2009 – 7:23 am in Analyst Calls, , , , , , , ,

Top 10 Early Bird Analyst Upgrades & Downgrades (BBBY, BTI, PAG, VRTX, MT, STD, CRXL, FMCN, MR, OWW)

These are the ten early bird analyst upgrades and downgrades we have seen early this morning with two and a half hours until the market opens:

  • Bed Bath & Beyond Raised (BBBY) Raised to Neutral from Sell at Goldman Sachs.
  • British American Tobacco (BTI) Raised to Buy at Goldman Sachs.
  • Penske Automotive (PAG) Raised to Buy at Goldman Sachs.
  • Vertex Pharmaceuticals (VRTX) Started as Buy at piper Jaffray.
  • Arcelor Mittal (MT) Cut to Sell from Buy at5 Citigroup.
  • Banco Santander (STD) Cut to Underweight at JPMorgan.
  • Crucell (CRXL) Cut to Hold at ING.
  • Focus Media (FMCN) Downgraded at Citigroup and Goldman Sachs (likely others as well).
  • Mindray Medical International (MR) Downgraded at Citigroup and Goldman Sachs.
  • Orbitz Worldwide (OWW) Cut to Sell at Goldman Sachs.

Jon C. Ogg
November 12, 2008

Posted on: November 12, 2008 – 7:06 am in Analyst Calls, , , , , , , , , ,

Biotech Business Daily (CHTP, CRXL, LLY, IOMI, MEDX, TRCA)

Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) falling today after first quarter earnings showed wider losses than first quarter 2007. Net loss was $8.7 million compared to a loss of $3.8 million in 2007. The wider loss was driven primarily through increased research and development expenses. Shares are down $0.44, or 8%, at $4.69. The 52-week range is $4.45 to $8.41.

Crucell NV (NASDAQ: CRXL) up today after cutting its net loss in half, posting $13.2 million in losses. The company has $120 million in new contracts for pediatric vaccine Quinvaxem to look forward to in the next two years. Revenues are on track to meet guidance. Also, the company announced this morning that Phase II testing of rabies monoclonal antibody combination product will begin in the Philipines. The product has already commenced testing in the U.S. Shares are up over 8% at $19.43 in mid-day trading. The 52-week range is $12.76 to $24.81.

Eli Lilly & Co. (NYSE: LLY) announced a partnership with TopCoder today, allowing Eli Lilly to outsource complex drug discovery through complex technology processes to the software developer. Shares are down less than 1% at $47.82. The 52-week range is $46.60 to $60.00.

Iomai Corporation (NASDAQ: IOMI) is soaring to new highs today after receiving a $189 million offer yesterday from vaccine maker Intercell AG which trades on the Vienna exchange. The offer of $6.60 per share is a 126% premium to the closing share price Monday of $2.92. As a result of the acquisition, Intercell will have full rights to Iomai’s diarrhea vaccine set to enter Phase III trials in early 2009. Shares are up a whopping 116% at $6.33 in mid-day trading on extremely high relative trading volume. The 52-week range for the biotech company is $0.70 to $4.70.

Medarex Inc. (NASDAQ: MEDX) received a boost after the company was upgraded by Needham & Co. to "Buy" from "Hold." Shares are up $0.56, or almost 8%, at $7.59. The 52-week range is $6.88 to $ 18.23.

Tercica Inc. (NASDAQ: TRCA) dropping over 15% today after posting wider net losses yesterday. The endocrine health biotech company generated a net loss of $17.5 million for the quarter, compared to a net loss of $12.4 million in the first quarter of 2007. Shares down $0.77 at $4.22 in early morning trading. The 52-week range is $4.27 to $8.11.

Rachel Lopez
May 12, 2008

Posted on: May 13, 2008 – 12:10 pm in Biotech, , , , , ,